The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: Therapeutic implications

British Journal of Haematology

Volumn 155, Issue 4, 2011, Pages 438-448

  Podar, Klaus ^a,b   Zimmerhackl, Alexander ^a   Fulciniti, Mariateresa ^a,c   Tonon, Giovanni ^d   Hainz, Ursula ^a   Tai, Yu Tzu ^a   Vallet, Sonia ^e   Halama, Niels ^b   Jäger, Dirk ^b   Olson, Dian L ^f   Sattler, Martin ^a   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a LeBow Institute for Myeloma Therapeutics   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BIOGEN   (United States)

Author keywords

Adhesion; Bone marrow microenvironment; Cell adhesion mediated drug resistance; Integrin 4; Multiple myeloma

Indexed keywords

ALPHA4 INTEGRIN; BORTEZOMIB; FIBRONECTIN; NATALIZUMAB; SOMATOMEDIN C; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SCID MOUSE; STROMA CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE MARROW CELLS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHA4; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054991119     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08864.x     Document Type: Article

References (37)

1. Abe, M., Hiura, K., Ozaki, S., Kido, S. & Matsumoto, T. (2009) Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production. Journal of Bone and Mineral Metabolism, 27, 16-23.
2. Burger, R., Guenther, A., Bakker, F., Schmalzing, M., Bernand, S., Baum, W., Duerr, B., Hocke, G.M., Steininger, H., Gebhart, E. & Gramatzki, M. (2001) Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. The Hematology Journal, 2, 42-53.
3. Carrasco, D.R., Tonon, G., Huang, Y., Zhang, Y., Sinha, R., Feng, B., Stewart, J.P., Zhan, F., Khatry, D., Protopopova, M., Protopopov, A., Sukhdeo, K., Hanamura, I., Stephens, O., Barlogie, B., Anderson, K.C., Chin, L., Shaughnessy, J.D., Jr, Brennan, C & Depinho, R.A. (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell, 9, 313-325.
4. Chauhan, D., Uchiyama, H., Urashima, M., Yamamoto, K. & Anderson, K.C. (1995) Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells. Stem Cells, 13(Suppl 2), 35-39.
5. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A. & Anderson, K.C. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood, 87, 1104-1112.
6. Damiano, J.S., Cress, A.E., Hazlehurst, L.A., Shtil, A.A. & Dalton, W.S. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 1658-1667.
7. Giancotti, F.G., Stepp, M.A., Suzuki, S., Engvall, E. & Ruoslahti, E. (1992) Proteolytic processing of endogenous and recombinant beta 4 integrin subunit. Journal of Cell Biology, 118, 951-959.
8. Gupta, D., Treon, S.P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.T., Lin, B., Lentzsch, S., Davies, F.E., Chauhan, D., Schlossman, R.L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D.I. & Anderson, K.C. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15, 1950-1961.
9. Harigaya, K. & Handa, H. (1985) Generation of functional clonal cell lines from human bone marrow stroma. Proceedings of the National Academy of Sciences of the United States of America, 82, 3477-3480.
10. Hynes, R.O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69, 11-25.
11. Kibler, C., Schermutzki, F., Waller, H.D., Timpl, R., Muller, C.A. & Klein, G. (1998) Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhesion and Communication, 5, 307-323.
12. Kyle, R.A. & Rajkumar, S.V. (2004) Multiple myeloma. New England Journal of Medicine, 351, 1860-1873.
13. Michigami, T., Shimizu, N., Williams, P.J., Niewolna, M., Dallas, S.L., Mundy, G.R. & Yoneda, T. (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood, 96, 1953-1960.
14. Mori, Y., Shimizu, N., Dallas, M., Niewolna, M., Story, B., Williams, P.J., Mundy, G.R. & Yoneda, T. (2004) Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood, 104, 2149-2154.
15. Nefedova, Y., Landowski, T.H. & Dalton, W.S. (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia, 17, 1175-1182.
16. Noborio-Hatano, K., Kikuchi, J., Takatoku, M., Shimizu, R., Wada, T., Ueda, M., Nobuyoshi, M., Oh, I., Sato, K., Suzuki, T., Ozaki, K., Mori, M., Nagai, T., Muroi, K., Kano, Y., Furukawa, Y. & Ozawa, K. (2009) Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene, 28, 231-242.
17. Olson, D.L., Burkly, L.C., Leone, D.R., Dolinski, B.M. & Lobb, R.R. (2005) Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Molecular Cancer Therapeutics, 4, 91-99.
18. Podar, K., Tai, Y.T., Lin, B.K., Narsimhan, R.P., Sattler, M., Kijima, T., Salgia, R., Gupta, D., Chauhan, D. & Anderson, K.C. (2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. The Journal of Biological Chemistry, 277, 7875-7881.
19. Podar, K., Tonon, G., Sattler, M., Tai, Y.T., Legouill, S., Yasui, H., Ishitsuka, K., Kumar, S., Kumar, R., Pandite, L.N., Hideshima, T., Chauhan, D. & Anderson, K.C. (2006) The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 103, 19478-19483.
20. Podar, K., Chauhan, D. & Anderson, K.C. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia, 23, 10-24.
21. Rajkumar, S.V., Leong, T., Roche, P.C., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Kyle, R.A., Gertz, M.A. & Greipp, P.R. (2000) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clinical Cancer Research, 6, 3111-3116.
22. Ransohoff, R.M. (2007) Natalizumab for multiple sclerosis. New England Journal of Medicine, 356, 2622-2629.
23. Ribatti, D., Vacca, A., Nico, B., Quondamatteo, F., Ria, R., Minischetti, M., Marzullo, A., Herken, R., Roncali, L. & Dammacco, F. (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer, 79, 451-455.
24. Rutgeerts, P., Vermeire, S. & Van Assche, G. (2009) Biological therapies for inflammatory bowel diseases. Gastroenterology, 136, 1182-1197.
25. Sanz-Rodriguez, F. & Teixido, J. (2001) VLA-4-dependent myeloma cell adhesion. Leukaemia & Lymphoma, 41, 239-245.
26. Schmidmaier, R. & Baumann, P. (2008) ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Current Medicinal Chemistry, 15, 978-990.
27. Schmidmaier, R., Morsdorf, K., Baumann, P., Emmerich, B. & Meinhardt, G. (2006) Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo. International Journal of Biological Markers, 21, 218-222.
28. Sezer, O., Niemoller, K., Eucker, J., Jakob, C., Kaufmann, O., Zavrski, I., Dietel, M. & Possinger, K. (2000) Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Annals of Hematology, 79, 574-577.
29. Tai, Y.T., Podar, K., Catley, L., Tseng, Y.H., Akiyama, M., Shringarpure, R., Burger, R., Hideshima, T., Chauhan, D., Mitsiades, N., Richardson, P., Munshi, N.C., Kahn, C.R., Mitsiades, C. & Anderson, K.C. (2003) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Research, 63, 5850-5858.
30. Tai, Y.T., Li, X.F., Catley, L., Coffey, R., Breitkreutz, I., Bae, J., Song, W., Podar, K., Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., Treon, S.P., Grewal, I.S., Munshi, N.C. & Anderson, K.C. (2005) Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Research, 65, 11712-11720.
31. Tassone, P., Neri, P., Carrasco, D.R., Burger, R., Goldmacher, V.S., Fram, R., Munshi, V., Shammas, M.A., Catley, L., Jacob, G.S., Venuta, S., Anderson, K.C. & Munshi, N.C. (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood, 106, 713-716.
32. Uchiyama, H., Barut, B.A., Chauhan, D., Cannistra, S.A. & Anderson, K.C. (1992) Characterization of adhesion molecules on human myeloma cell lines. Blood, 80, 2306-2314.
33. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. & Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503-508.
34. Vacca, A., Di Loreto, M., Ribatti, D., Di Stefano, R., Gadaleta-Caldarola, G., Iodice, G., Caloro, D. & Dammacco, F. (1995) Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. American Journal of Hematology, 50, 9-14.
35. Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. & Dammacco, F. (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 3064-3073.
36. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. & Shaughnessy, J.D., Jr (2006) The molecular classification of multiple myeloma. Blood, 108, 2020-2028.
37. Zhang, J., Sattler, M., Tonon, G., Grabher, C., Lababidi, S., Zimmerhackl, A., Raab, M.S., Vallet, S., Zhou, Y., Cartron, M.A., Hideshima, T., Tai, Y.T., Chauhan, D., Anderson, K.C. & Podar, K. (2009) Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Research, 69, 5082-5090.